Gonadorelin (GnRH) (10mg)

Description

Gonadorelin Peptide – Mechanism, Benefits, and Research

Gonadorelin Peptide is the synthetic form of the naturally occurring gonadotropin-releasing hormone (GnRH). GnRH regulates the secretion of gonadotropins, specifically follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which manage the endocrine functions and maturation of the gonads. Researchers have created Gonadorelin to mimic the natural hormone, offering potential for reproductive regulation, endocrine studies, and research on hormonal therapies.

What is Gonadorelin Peptide?

Gonadorelin Peptide is a synthetic decapeptide consisting of ten amino acids in a sequential chain. It is structurally identical to endogenous GnRH, which is why it is classified as a GnRH agonist. This peptide may stimulate the synthesis and release of gonadotropins by activating GnRH receptors in the anterior pituitary gland.

Prolonged or excessive exposure, however, may downregulate GnRH receptors, temporarily reducing LH and FSH secretion. Researchers continue to explore the peptide’s potential in reproductive health, hormone regulation, and experimental therapies.

Chemical Makeup

• Molecular Formula: C55H75N17O13

• Molecular Weight: 1182.31 g/mol

• Other Names: Growth Hormone Releasing Factor, Somatocrinin, Somatoliberin

Gonadorelin Peptide and Post-Cycle Recovery

Exogenous androgens can suppress the hypothalamic-pituitary-gonadal (HPG) axis. This suppression reduces LH, FSH, and endogenous testosterone. Studies suggest that Gonadorelin Peptide can stimulate the HPG axis to recover faster. In one study, androgen-suppressed subjects showed significant increases in LH, FSH, and testosterone within a short exposure to Gonadorelin, with improvements lasting over 12 months.

Impact on Testicular Function

Intermittent Gonadorelin exposure may mimic natural GnRH pulses. This can activate the pituitary to produce LH and FSH and stimulate testosterone production by the testes. Clinical studies suggest that consistent Gonadorelin treatment over several months may improve spermatogenesis and even facilitate testicular descent, showing roughly a 40% success rate in HPG axis maturation.

Potential Role in Cancer Research

Gonadorelin Peptide may influence hormone-sensitive cancer pathways. By modulating LH and FSH levels, it could reduce exposure of cells to estrogen and testosterone, potentially lowering the risk of breast or prostate cancer development. Experimental studies indicate that GnRH agonists like Gonadorelin may help reduce mitogen-mediated proliferation in hormone-sensitive cells.

Gonadorelin Peptide and Spermatogenesis

In a clinical study, male subjects receiving a GnRH analog similar to Gonadorelin showed temporary reductions in sperm count, including azoospermia in some cases. After treatment ended, sperm counts returned to normal. These results suggest that Gonadorelin Peptide can act as a reversible contraceptive when combined with certain testosterone therapies.

Neuroprotective Potential

Luteinizing hormone levels may impact hippocampal function, affecting memory. Research suggests that selectively modulating LH and FSH using Gonadorelin Peptide could help protect brain function while maintaining hormonal balance, unlike full testosterone suppression.

Diagnostics and Hormonal Testing

Gonadorelin Peptide can be used in research to assess pituitary function. Clinical trials show that the peptide can stimulate gonadotropin release in both healthy and amenorrheic subjects, offering insight into hypothalamic-pituitary axis functionality.

Conclusion

Gonadorelin Peptide is a synthetic GnRH analog with significant research potential. It may regulate gonadotropin secretion, assist in post-cycle recovery, support testicular function, provide neuroprotective effects, and even contribute to cancer research studies. Its reversible and targeted action on the HPG axis makes it a valuable tool for laboratory and clinical investigations. You may also be interested in our related research peptides, including bpc 157, bpc 157 peptide, Tesamorelin, ghk cu peptide, tesamorelin peptide, cjc 1295 ipamorelin, mots-c, semax, and PT-141. For research use only.

Gonadorelin peptide is for research purposes only. Please adhere to all safety guidelines and review Terms and Conditions before ordering.

References:

1. 1. Marques P, Skorupskaite K, George JT, et al. Physiology of GNRH and Gonadotropin Secretion. [Updated 2018 Jun 19]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK279070/
   2. National Center for Biotechnology Information. PubChem Compound Summary for CID 638793, Gonadorelin.
   3. Philip GA Thomas, Alain Fontbonne, Drugs and reproduction. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/gonadorelin-acetate
   4. van Breda, E., Keizer, H. A., Kuipers, H., & Wolffenbuttel, B. H. (2003). Androgenic anabolic steroid use and severe hypothalamic-pituitary dysfunction: a case study. International journal of sports medicine, 24(3), 195–196. https://doi.org/10.1055/s-2003-39089
   5. Blumenfeld, Z., Makler, A., Frisch, L., & Brandes, J. M. (1988). Induction of spermatogenesis and fertility in hypogonadotropic azoospermic men by intravenous pulsatile gonadotropin-releasing hormone (GnRH). Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2(2), 151–164. https://doi.org/10.3109/09513598809023623
   6. Zhang, L., Cai, K., Wang, Y., Ji, W., Cheng, Z., Chen, G., & Liao, Z. (2019). The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men. American journal of men’s health, 13(1), 1557988318818280. https://doi.org/10.1177/1557988318818280
   7. Muzzi, G., Bartolotta, E., Cherubini, V., & Lomiento, D. (1990). Effetti del trattamento con LH-RH sintetico spray nasale nel criptorchidismo [Effects of the treatment using synthetic LH-RH nasal spray in cryptorchism]. La Pediatria medica e chirurgica : Medical and surgical pediatrics, 12(1), 53–55.
   8. Lepor, Herbert. “Comparison of single-agent androgen suppression for advanced prostate cancer.” Reviews in urology vol. 7 Suppl 5,Suppl 5 (2005): S3-S12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1477619/
   9. Spicer DV, Pike MC. Sex steroids and breast cancer prevention. J Natl Cancer Inst Monogr. 1994;(16):139-47. https://pubmed.ncbi.nlm.nih.gov/7999456/
   10. Secreto G, Sieri S, Agnoli C, Grioni S, Muti P, Zumoff B, Sant M, Meneghini E, Krogh V. A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women. Breast Cancer Res Treat. 2016 Aug;158(3):553-61. https://pubmed.ncbi.nlm.nih.gov/27393623/
   11. Zerbib M. Analogues de la GnRH dans le traitement du cancer de la prostate [GnRH analogs and prostate cancer treatment]. Ann Urol (Paris). 2005 Oct;39 Suppl 3:S66-72. French. doi: 10.1016/s0003-4401(05)80011-7. https://pubmed.ncbi.nlm.nih.gov/16302714/
   12. Bhasin S, Yuan QX, Steiner BS, Swerdloff RS. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in men: effects of long term treatment with GnRH agonist infusion and androgen. J Clin Endocrinol Metab. 1987 Sep;65(3):568-74. https://pubmed.ncbi.nlm.nih.gov/3114307/